VDR and leukemia: It then enters the bloodstream where it is metabolized to 25-hydroxyvitamin D in the liver, which then travels to the kidneys, where it is metabolized to 1,25-dihydroxyvitamin D. In regard to prevention of leukemias, this molecule acts on vitamin D receptors in bone marrow to produce e-cadherins [21], which make up adherens junctions that bridge intracellular actin cytoskeletons.